Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679517 | 0.83 | CYP2C9 (0.35) | — | |
| SCHEMBL9850087 | 0.72 | SIGMAR1 (0.41) | OPRM1 | |
| SCHEMBL9850089 | 0.72 | ATM (0.40) | — | |
| SCHEMBL28580942 | 0.69 | PTGS1 (0.38) | HSD11B1PTGS1RORCOPRM1 | |
| SCHEMBL9721742 | 0.68 | SLC6A3 (0.36) | HSD11B1 | |
| SCHEMBL27538480 | 0.68 | PTGS1 (0.36) | PTGS1AKR1B1 | |
| SCHEMBL30211173 | 0.67 | SMN1; SMN2 (0.42) | OPRM1GAA | |
| SCHEMBL6889536 | 0.65 | LIPG (0.42) | HSD11B1NR1I2RORCOPRM1 | |
| SCHEMBL577270 | 0.63 | L3MBTL1 (0.35) | — | |
| SCHEMBL1533060 | 0.62 | HCAR3 (0.32) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992618-B1 | POLYCYCLIC CINNAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-7973033-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2011-05-12 | — | — | US | disclosed |
| US-7897632-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2010-07-01 | — | — | US | disclosed |
| US-7713993-B2 | Multi-cycle cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1992618-A1 | POLYCYCLIC CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | HSD11B1 95/4885PTGS1 837/4885NR1I2 104/4885 |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | BACE1, APP, PSEN1 | HSD11B1 95/4885PTGS1 837/4885NR1I2 104/4885 |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | HSD11B1 95/4885PTGS1 837/4885NR1I2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.